文献速递炎症性肠病

克罗恩病患者中阿达木单抗血清谷浓度及抗药抗体监测作为个体化药代动力学的意义:DIAMOND试验亚组分析

Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
PubMed 文献 · Aliment Pharmacol Ther · 2017-09-08

基于DIAMOND试验的亚组分析,评估克罗恩病患者第26周阿达木单抗谷浓度及抗阿达木单抗抗体(AAA)与第52周临床缓解的关联。第52周缓解者第26周谷浓度显著高于未缓解者(7.7±3.3 μg/mL vs 5.4±4.3 μg/mL,P<.001)。第26周AAA出现显著影响第52周缓解(P=.021)。

要点

  • 第52周缓解者第26周阿达木单抗谷浓度显著高于未缓解者(7.7±3.3 μg/mL vs 5.4±4.3 μg/mL,P<.001)。
  • 阿达木单抗谷浓度5.0 μg/mL预测缓解的敏感性为80.2%、特异性为55.6%。
  • 第26周AAA出现显著影响第52周缓解(P=.021),且与阿达木单抗谷浓度强相关。

核心结论

  • 阿达木单抗谷浓度及AAA出现与临床缓解显著相关。
  • 较高的6TGN影响AAA阴性。
  • 联合治疗在部分相关方面对克罗恩病患者有益。

研究设计与样本

  • 本研究为DIAMOND试验的亚组分析,使用第26周阿达木单抗谷浓度、AAA及第12周红细胞内6-硫鸟嘌呤核苷酸(6TGN)数据进行。
  • 采用多元回归模型和受试者工作特征分析,识别影响阿达木单抗谷浓度和AAA的因素及预测疾病活动的阿达木单抗阈值。
  • 研究注册号:UMIN Registration No. 000005146。

主要发现

  • 第52周缓解者与未缓解者第26周阿达木单抗谷浓度分别为7.7±3.3 μg/mL与5.4±4.3 μg/mL,差异显著(P<.001)。
  • 阿达木单抗谷浓度5.0 μg/mL预测缓解的敏感性为80.2%、特异性为55.6%。
  • 第26周AAA出现显著影响第52周缓解(P=.021),且与阿达木单抗谷浓度强相关。
  • 女性性别和体重增加与低阿达木单抗谷浓度独立相关,女性性别与AAA出现相关。
  • 6TGN阈值>222.5 p mol/8×10⁸红细胞预测AAA阴性的敏感性为100%、特异性为60.6%。

关键数值与推荐

  • 阿达木单抗谷浓度5.0 μg/mL为预测缓解的阈值,敏感性80.2%、特异性55.6%。
  • 6TGN阈值>222.5 p mol/8×10⁸红细胞预测AAA阴性的敏感性100%、特异性60.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Significance of monitoring adalimumab trough levels and anti-adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD) patients remained unclear. AIM: To evaluate the association of adalimumab trough levels and AAA at week 26 with clinical remission at week 52, the effect of azathiopurine on AAA and factors influencing trough levels in CD patients in the DIAMOND trial. METHODS: We performed this study using adalimumab trough levels, AAA at week 26 and 6-thioguanine nucleotide (TGN) in red blood cells at week 12. A multiple regression model and receiver operating analysis was performed to identify factors influencing adalimumab trough levels and AAA, and adalimumab thresholds for predicting disease activity. RESULTS: There was a significant difference of adalimumab trough level at week 26 between patients with disease remission and without at week 52 (7.7 ± 3.3 μg/mL vs 5.4 ± 4.3 μg/mL: P <.001). Adalimumab trough level of 5.0 μg/mL yielded optimal sensitivity and specificity for remission prediction (80.2% and 55.6%, respectively). AAA development at week 26 significantly affected remission at week 52 (P = .021), which was strongly associated with adalimumab trough levels. Female gender and increasing body weight were independently associated with low adalimumab trough levels, and female gender was associated with AAA development. A cut-off 6TGN level of >222.5 p mol/8 ×108 RBCs yielded sensitivity (100%) and specificity (60.6%) for AAA negativity. CONCLUSION: Adalimumab trough levels and AAA occurrence were significantly associated with clinical remission. Higher 6TGN affected AAA negativity. The combination therapy is beneficial in some relevant aspects for CD patients. (UMIN Registration No. 000005146).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017. PMID: 28884856. doi:10.1111/apt.14318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。